WW upgraded by Morgan Stanley with a new price target
$WW
Other Consumer Services
Consumer Discretionary
Morgan Stanley upgraded WW from Equal-Weight to Overweight and set a new price target of $13.00 from $5.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2025 | Market Perform | CJS Securities | |
| 7/26/2024 | $6.50 → $1.25 | Overweight → Equal-Weight | Morgan Stanley |
| 1/3/2024 | $8.00 | Underweight | Barclays |
| 12/20/2023 | $14.00 | Buy | Guggenheim |
| 9/27/2023 | $4.00 → $10.00 | Sell → Hold | Craig Hallum |
| 7/26/2023 | $5.00 → $13.00 | Equal-Weight → Overweight | Morgan Stanley |
| 4/11/2023 | $3.80 → $13.00 | Neutral → Buy | Goldman |
| 3/8/2023 | $4.00 | Hold → Sell | Craig Hallum |
4 - WW INTERNATIONAL, INC. (0000105319) (Issuer)
4 - WW INTERNATIONAL, INC. (0000105319) (Issuer)
4 - WW INTERNATIONAL, INC. (0000105319) (Issuer)
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weight Watchers"), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company's newly FDA-approved oral GLP-1, Foundayo® (orforglipron) through its Med+ offering and affiliated medical groups. The addition gives members a new once-daily, injection-free option for adults with obesity or overweight with weight-related medical problems and further expands the company's growing portfolio of FDA-approved oral GLP-1 treatments, all within a clinically supported program designed to help them succeed. Through Weight Watchers Med+, clinically eligible memb
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weight Watchers" or the "Company"), the global leader in science-backed weight management, today announced the following updates to the composition of its Board of Directors' standing committees following the appointments of Lisa Gavales and Sue Gove as independent directors: Audit Committee: Gene Davis (Chair), Sue Gove, Carney Hawks and Nikolaj Sjoqvist;Compensation and Benefits Committee: Carney Hawks (Chair), Gene Davis and Lisa Gavales;Nominating and Corporate Governance Committee: Nikolaj Sjoqvist (Chair), Gene Davis and Sue Gove; andStrategy and Finance Committee: Gene Davis (Chair), Lisa Gavales, Car
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weight Watchers" or the "Company"), the global leader in science-backed weight management, today announced that it has appointed accomplished executives, Lisa Gavales and Sue Gove, as independent members of the Company's Board of Directors, effective April 7, 2026. Ms. Gavales and Ms. Gove will serve as directors until the Company's 2026 annual meeting of shareholders and are expected to stand for election at the annual meeting. Following these appointments, the Board consists of six directors, all of whom are independent. Lisa Gavales and Sue Gove are highly regarded consumer brand leaders with distinct exp
CJS Securities initiated coverage of WW with a rating of Market Perform
Morgan Stanley downgraded WW from Overweight to Equal-Weight and set a new price target of $1.25 from $6.50 previously
Barclays initiated coverage of WW with a rating of Underweight and set a new price target of $8.00
8-K/A - WW INTERNATIONAL, INC. (0000105319) (Filer)
8-K - WW INTERNATIONAL, INC. (0000105319) (Filer)
8-K - WW INTERNATIONAL, INC. (0000105319) (Filer)
4 - WW INTERNATIONAL, INC. (0000105319) (Issuer)
4 - WW INTERNATIONAL, INC. (0000105319) (Issuer)
4 - WW INTERNATIONAL, INC. (0000105319) (Issuer)
2025 Total Revenue and Adjusted EBITDA1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026 Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA1 of $18 million and Adjusted EBITDA Margin1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weigh
NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weight Watchers" or the "Company") will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Monday, March 16, 2026. Weight Watchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company's corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days. About Weight WatchersWeight Watchers is the global leader in science-backed weight management, offering an integrated support system b
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("WeightWatchers," "WW," or the "Company") will release its results for the third quarter 2025 ended September 30, 2025, before market open on Thursday, November 6, 2025. WeightWatchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company's corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days. About WeightWatchersWeightWatchers is the global leader in science-backed weight management, offering an integrated support system that co
SC 13G/A - WW INTERNATIONAL, INC. (0000105319) (Subject)
SC 13G/A - WW INTERNATIONAL, INC. (0000105319) (Subject)
SC 13G - WW INTERNATIONAL, INC. (0000105319) (Subject)
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weight Watchers" or the "Company"), the global leader in science-backed weight management, today announced that it has appointed accomplished executives, Lisa Gavales and Sue Gove, as independent members of the Company's Board of Directors, effective April 7, 2026. Ms. Gavales and Ms. Gove will serve as directors until the Company's 2026 annual meeting of shareholders and are expected to stand for election at the annual meeting. Following these appointments, the Board consists of six directors, all of whom are independent. Lisa Gavales and Sue Gove are highly regarded consumer brand leaders with distinct exp
Office of the CEO Established to Oversee Business Operations Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("Weight Watchers" or the "Company"), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors ("the Board"). These actions follow Tara Comonte's departure from the Company, effective March 31, 2026. The Company's Board of Directors has initiated a comprehensive search for a permanent successor with the support of a l
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ:WW) ("WeightWatchers" or the "Company"), the global leader in science-backed weight management, today announced the launch of WeightWatchers for Menopause, a groundbreaking programme that sets a new standard in women's health, designed to support women through every stage of the menopause journey, from perimenopause to post-menopause. To launch the programme, WeightWatchers is partnering with Grammy and Emmy Award-winning and Oscar-nominated actress, producer, entrepreneur, and health advocate Queen Latifah as its first official spokeswoman. "Menopause has been a new journey for me—one that's changed how I see a